|
Remdesivir
|
Viral RNA polymerase inhibitor
|
Hepatitis C
|
|
Favipiravir
|
Viral RNA polymerase inhibitor
|
Influenza
|
|
Hydroxychloroquine
|
MAPK inhibitor
|
Malaria
|
|
Lanadelumab
|
Inhibition of kallikrein
|
Hereditary angioedema
|
|
Ruxolitinib
|
JAK1/2 inhibitor
|
Myelofibrosis
|
|
Tocilizumab and sarilumab
|
IL-6 inhibitor
|
Rheumatoid arthritis
|
|
Anakira
|
IL-1ß-inhibitor
|
Rheumatoid arthritis
|
|
Lopinavir and ritonavir
|
Viral protease inhibitors
|
HIV
|
|
Oseltamivir
|
Neuraminidase inhibitor
|
Influenza
|
|
Imatinib
|
Abl kinase inhibitor
|
Leukemia
|
|
Cyclosporin A
|
Calcineurin inhibitor
|
Various (auto)-immune diseases
|
|
Nafamostat and camostat
|
TMPRSS2 inhibitor (viral membrane fusion inhibitor)
|
Anticoagulation
|
|
Enoxaparin and Rivaroxaban
|
Factor Xa inhibitor
|
Anticoagulation
|
|
Ravulizumab
|
Complement (C5) inhibitor
|
Paroxysmal nocturnal hemoglobinuria
|
|
Disulfiram
|
Inhibition of viral proteolysis
|
Chronic alcoholism
|
|
Ivermectin
|
Inhibition of viral replication
|
Onchocerciasis
|
